Turning low-molecular-weight drugs into prolonged acting prodrugs by reversible pegylation: A study with gentamicin

Journal of Medicinal Chemistry

Volumn 51, Issue 14, 2008, Pages 4300-4305

  Marcus, Yonit ^a   Sasson, Keren ^a   Fridkin, Mati ^a   Shechter, Yoram ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; MACROGOL; MACROGOL 400; PRODRUG;

ANIMAL EXPERIMENT; ARTICLE; COVALENT BOND; DERIVATIZATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG POTENCY; DRUG RELEASE; DRUG URINE LEVEL; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; NONHUMAN; PEGYLATION; RAT; TECHNOLOGY;

ANIMALS; ESCHERICHIA COLI; GENTAMICINS; GLOMERULAR FILTRATION RATE; HALF-LIFE; HYDROLYSIS; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR WEIGHT; POLYETHYLENE GLYCOLS; PRODRUGS; RATS; RATS, WISTAR;

EID: 47749127296     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8002558     Document Type: Article

References (14)

1. Benet, L. Z.; Mitchell, T. R.; Scheiner, L. B. In The Pharmacological Basis of Therapeutics; Goodman, L. A. E., Gilman, T. W., Rall, A. S., Nies, A. S., Taylor, G. M., Eds.; Pergamon Press: New York, 1990; pp 3-32.
2. Delgado, C.; Francis, G. E.; Derek, F. F. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. 1992, 9, 249-304.
3. Fuerteges, F.; Abuchowski, A. The clinical efficacy of poly(ethylene glycol)-modified proteins. J. Controlled Release 1990, 11, 139-148.
4. Fung, W.-J.; Porter, J. E.; Bailon, P. Strategies for the preparation and characterization of polyethylene glycol (PEG) conjugated pharmaceutical proteins. Polym. Prepr. 1997, 38, 565-566.
5. Bailon, P.; Berthold, W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm. Sci. Technol. Today 1998, 1, 352-356.
6. Clark, R.; Olson, K.; Fuh, G.; Marian, M.; Mortensen, D.; Teshima, G. Long-acting growth hormones produced by conjugation with polyethylene glycol. J. Biol. Chem. 1996, 271, 21969-21977.
7. Bailon, P.; Palleroni, A.; Schaffer, C. A.; Spence, C. L.; Fung, W.-J.; Porter, J. E.; et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Biochonjugate Chem. 2001, 12, 195-202.
8. Tsubery, H.; Mironchik, M.; Fridkin, M.; Shechter, Y. Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. J. Biol. Chem. 2004, 279, 38118-38124.
9. Peleg-Shulman, T.; Tsubery, H.; Mironchik, M.; Fridkin, M.; Schreiber, G.; Shechter, Y. Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. J. Med. Chem. 2004, 47, 4897-4904.
10. Shechter, Y.; Tsubery, H.; Mironchik, M.; Rubinstein, M.; Fridkin, M. Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice. FEBS Lett. 2005, 579, 2439-2444.
11. Nesher, M.; Vachutinsky, Y.; Fridkin, G.; Schwarz, Y.; Sasson, K.; Fridkin, M.; Shechter, Y.; Lichtstein, D. Reversible pegylation prolongs the hypotensive effect of atrial natriuretic peptide. Bioconjugate Chem. 2008, 19, 342-348.
12. Shechter, Y.; Mironchik, M.; Saul, A.; Gershonov, E.; Precido-Patt, L.; Sasson, K.; Tsubery, H.; Mester, B.; Kapitkovsky, A.; Rubinraut, S.; Vachutinsky, Y.; Fridkin, G.; Fridkin, M. New technologies to prolong life-time of peptide and protein drugs in-vivo. Int. J. Pept. Res. Ther. 2007, 13, 105-117.
13. Edson, R. S.; Terrell, C. L. The aminoglycosides. Mayo Clin. Proc. 1999, 74, 519-528.
14. Jolley, M. E.; Stroupe, S. D.; Wang, C.-H. J.; Panes, H. N.; Keegan, C. L.; Schmidt, R. L.; Schwenzer, K. S. Fluorescence polarization immunoassay I. Monitoring aminoglycoside anti-biotics in serum and plasma. Clin. Chem. 1981, 27, 1190-1197.